Home
Forms Library
Nucynta ER REMS - Food and Drug Administration - fda

Nucynta ER REMS - Food and Drug Administration - fda 2025

Nucynta ER REMS - Food and Drug Administration - fda Preview on Page 1

Show details

4 out of 5

40 votes

The document outlines the Risk Evaluation and Mitigation Strategy (REMS) for NUCYNTA ER (tapentadol), an opioid analgesic approved by the FDA. It aims to educate patients and healthcare professionals about the risks of abuse, misuse, overdose, and addiction associated with NUCYNTA ER. The REMS includes mandatory training for prescribers, a Medication Guide for patients, and guidelines for safe use, storage, and disposal of the medication. It emphasizes proper patient selection, dosing instructions, and monitoring for signs of misuse or addiction.

Here's how it works

01. Edit your form online

Type text, add images, blackout confidential details, add comments, highlights and more.

02. Sign it in a few clicks

Draw your signature, type it, upload its image, or use your mobile device as a signature pad.

03. Share your form with others

Send it via email, link, or fax. You can also download it, export it or print it out.

How to edit Nucynta ER REMS - Food and Drug Administration - fda in PDF format online

Ease of Setup

DocHub User Ratings on G2

Ease of Use

DocHub User Ratings on G2

Handling paperwork with our extensive and user-friendly PDF editor is easy. Make the steps below to fill out Nucynta ER REMS - Food and Drug Administration - fda online easily and quickly:

Sign in to your account. Log in with your email and password or create a free account to test the service before choosing the subscription.
Upload a form. Drag and drop the file from your device or import it from other services, like Google Drive, OneDrive, Dropbox, or an external link.
Edit Nucynta ER REMS - Food and Drug Administration - fda. Quickly add and highlight text, insert pictures, checkmarks, and icons, drop new fillable areas, and rearrange or remove pages from your document.
Get the Nucynta ER REMS - Food and Drug Administration - fda accomplished. Download your modified document, export it to the cloud, print it from the editor, or share it with others using a Shareable link or as an email attachment.

Take advantage of DocHub, one of the most easy-to-use editors to quickly handle your paperwork online!

be ready to get more

Complete this form in 5 minutes or less

Get form

Got questions?

We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.

Is NUCYNTA the same as tapentadol?

Tapentadol (Nucynta) is a centrally-acting opioid analgesic approved for the relief of moderate to severe pain in adults.

Is Nucynta stronger than oxycodone?

(1) It works similarly to oxycodone, as it binds to the same receptors in the brain and body. However, Nucynta can provide further relief for chronic pain because it is also a norepinephrine reuptake inhibitor.

How long has Nucynta been on the market?

Tapentadol HCl immediate release (IR) (Nucynta, PriCara), a centrally acting analgesic, was approved by the FDA on November 20, 2008, for the relief of moderate-to-severe acute pain.

Is Nucynta being discontinued?

The Food and Drug Administration (FDA or Agency) has determined that NUCYNTA (tapentadol hydrochloride) solution, equivalent (eq) 20 milligrams (mg) base/milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness.

When was tapentadol approved by the FDA?

Tapentadol was first approved for the US market in 2008. The safety and efficacy of tapentadol for the treatment of acute and chronic pain in adults has been well established.

When was NUCYNTA FDA approved?

It is taken twice daily and available in 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths. NUCYNTA (tapentadol immediate-release tablets) was approved by the FDA on November 20, 2008, for the relief of moderate to severe acute pain in patients 18 years of age or older.

What class of drug is Nucynta ER?

NUCYNTA ER contains tapentadol, a Schedule II controlled substance. As an opioid, NUCYNTA ER exposes users to the risks of Addiction, Abuse, and Misuse.

Nucynta ER REMS - Food and Drug Administration - fda 2025

Here's how it works